ENTRY       D11971                      Drug
NAME        Tozinameran (JAN);
            COVID-19 mRNA vaccine (nucleoside-modified);
            Tozinameran and riltozinameran;
            Tozinameran and famtozinameran;
            Tozinameran and raxtozinameran;
            Comirnaty (TN);
            Pfizer-biontech Covid-19 vaccine (TN)
PRODUCT     COMIRNATY (Pfizer Laboratories Div Pfizer)
  OTHER     ORIGINAL AND OMICRON BA.4/BA.5 (Pfizer Manufacturing Belgium NV)
CLASS       Antiviral
             DG03172  COVID-19 vaccine
REMARK      Therapeutic category: 6313
            ATC code: J07BN01
            Product: D11971<JP/US>
EFFICACY    Active immunization (SARS-CoV-2)
  DISEASE   Prevention of COVID-19 [DS:H02398]
COMMENT     Tozinameran is mRNA encoding full length of spike protein analog of SARS-CoV-2
TARGET      SARS-CoV-2 spike glycoprotein [KO:K24152]
  PATHWAY   ko03230(K24152)  Viral genome structure
            ko03262(K24152)  Virion - Coronavirus
            ko05171(K24152)  Coronavirus disease - COVID-19
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J07 VACCINES
               J07B VIRAL VACCINES
                J07BN Covid-19 vaccines
                 J07BN01 Covid-19, RNA-based vaccine
                  D11971  Tozinameran (JAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Vaccines
               COVID-19
                COVID-19 Vaccine (mRNA)
                 D11971  Tozinameran (JAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              63  Biological preparations
               631  Vaccines
                6313  Viral vaccines
                 D11971  Tozinameran (JAN)
            Drug groups [BR:br08330]
             Antiviral
              DG03172  COVID-19 vaccine
               D11971  Tozinameran
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11971
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11971
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11971
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11971
DBLINKS     CAS: 2417899-77-3
///
